GLSI
Greenwich LifeSciences, Inc.
Pharmaceutical PreparationsNasdaq<br>Emerging growth company
Total Trades
89
Buys
89
Sells
0
Largest Trade
$1M+
Insiders
4
Institutional Funds
37
Inst. Value
$1M+
Activist Filings
1
Insider Trades
| Insider | Title | Type | Value | Shares | Price | Date |
|---|---|---|---|---|---|---|
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 1K | $18.68 | Feb 14, 2023 |
| Thompson Jaye | VP Clinical Reg Af… | BUY | $1K–$15K | 250 | $20.84 | Feb 7, 2023 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 2K | $19.35 | Jan 31, 2023 |
| Thompson Jaye | VP Clinical Reg Af… | BUY | $1K–$15K | 250 | $19.20 | Jan 30, 2023 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 2K | $17.37 | Jan 24, 2023 |
| Thompson Jaye | VP Clinical Reg Af… | BUY | $1K–$15K | 250 | $16.50 | Jan 17, 2023 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 2K | $15.18 | Jan 10, 2023 |
| Patel Snehal | CEO and CFO | BUY | $50K–$100K | 4K | $15.19 | Jan 3, 2023 |
| Patel Snehal | CEO and CFO | BUY | $1K–$15K | 1K | $13.01 | Dec 20, 2022 |
| Thompson Jaye | VP Clinical Reg Af… | BUY | $1K–$15K | 250 | $12.94 | Dec 20, 2022 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 2K | $13.11 | Dec 13, 2022 |
| Patel Snehal | CEO and CFO | BUY | $1K–$15K | 1K | $13.84 | Dec 6, 2022 |
| Thompson Jaye | VP Clinical Reg Af… | BUY | $1K–$15K | 250 | $13.98 | Dec 6, 2022 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 2K | $8.79 | Nov 4, 2022 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 3K | $9.75 | Oct 17, 2022 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 2K | $9.72 | Oct 11, 2022 |
| Patel Snehal | CEO and CFO | BUY | $1K–$15K | 1K | $9.46 | Oct 4, 2022 |
| Patel Snehal | CEO and CFO | BUY | $1K–$15K | 1K | $9.23 | Oct 3, 2022 |
| Patel Snehal | CEO and CFO | BUY | $100K–$500K | 29K | $9.13 | Jun 27, 2022 |
| Patel Snehal | CEO and CFO | BUY | $50K–$100K | 8K | $7.13 | Jun 17, 2022 |
| Patel Snehal | CEO and CFO | BUY | $50K–$100K | 12K | $7.91 | Jun 15, 2022 |
| Patel Snehal | CEO and CFO | BUY | $50K–$100K | 12K | $8.33 | Jun 13, 2022 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 5K | $10.90 | Jun 10, 2022 |
| Patel Snehal | CEO and CFO | BUY | $50K–$100K | 6K | $8.55 | Jun 8, 2022 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 7K | $7.38 | Jun 3, 2022 |
| Daugherty Frank Joseph | Chief Medical Offi… | BUY | $15K–$50K | 1K | $16.25 | Apr 26, 2022 |
| Patel Snehal | CEO and CFO | BUY | $50K–$100K | 6K | $16.09 | Apr 22, 2022 |
| Patel Snehal | CEO and CFO | BUY | $100K–$500K | 6K | $16.74 | Apr 21, 2022 |
| Thompson Jaye | VP Clinical Reg Af… | BUY | $1K–$15K | 500 | $16.74 | Apr 20, 2022 |
| Patel Snehal | CEO and CFO | BUY | $100K–$500K | 6K | $19.80 | Feb 14, 2022 |
| Patel Snehal | CEO and CFO | BUY | $50K–$100K | 5K | $19.59 | Feb 8, 2022 |
| Thompson Jaye | VP Clinical Reg Af… | BUY | $1K–$15K | 500 | $18.47 | Feb 1, 2022 |
| Thompson Jaye | VP Clinical Reg Af… | BUY | $1K–$15K | 500 | $16.33 | Jan 24, 2022 |
| Hallock Kenneth | Director | BUY | $1K–$15K | 300 | $16.32 | Jan 24, 2022 |
| Thompson Jaye | VP Clinical Reg. A… | BUY | $1K–$15K | 500 | $18.87 | Jan 19, 2022 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 1K | $19.99 | Jan 18, 2022 |
| Thompson Jaye | VP Clinical Reg. A… | BUY | $15K–$50K | 1K | $19.99 | Jan 14, 2022 |
| Daugherty Frank Joseph | Chief Medical Offi… | BUY | $15K–$50K | 1K | $19.99 | Jan 14, 2022 |
| Patel Snehal | CEO and CFO | BUY | $15K–$50K | 2K | $23.82 | Jan 4, 2022 |
🔓Seeing ranges? Sign in for exact trade values — free forever
Institutional Ownership
13F filings as of Dec 31, 2025 · 37 funds holding
| Fund | Shares | Value | Type |
|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 132K | $1M+ | SH |
| STATE STREET CORP | 98K | $1M+ | SH |
| VANGUARD GROUP INC | 45K | $500K+ | SH |
| Virtu Financial LLC | 29K | $500K+ | SH |
| Man Group plc | 28K | $500K+ | SH |
| GOLDMAN SACHS GROUP INC | 22K | $100K–$500K | SH |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 19K | $100K–$500K | SH |
| MORGAN STANLEY | 10K | $100K–$500K | SH |
| BARCLAYS PLC | 10K | $100K–$500K | SH |
| RHUMBLINE ADVISERS | 8K | $100K–$500K | SH |
| NEW YORK STATE COMMON RETIREMENT FUND | 6K | $100K–$500K | SH |
| STRS OHIO | 6K | $100K–$500K | SH |
| Bank of New York Mellon Corp | 5K | $100K–$500K | SH |
| Police & Firemen's Retirement System of New Jersey | 3K | $50K–$100K | SH |
| BlackRock, Inc. | 3K | $50K–$100K | SH |
| Newbridge Financial Services Group, Inc. | 2K | $15K–$50K | SH |
| BNP PARIBAS FINANCIAL MARKETS | 2K | $15K–$50K | SH |
| UBS Group AG | 1K | $15K–$50K | SH |
| DEUTSCHE BANK AG\ | 1K | $15K–$50K | SH |
| WELLS FARGO & COMPANY/MN | 1K | $15K–$50K | SH |
Activist & 5%+ Owners
SC 13D/13G filings — investors holding 5%+ of outstanding shares
SC 13G · Jun 22, 2022
17.7%
2.3M shares